$Citius Pharmaceuticals, Inc.(CTXR)$ 

🔥 **Revolutionary Therapy, Addressing Unresolved Medical Pain: Citius is Rewriting the Rules of Patient Survival**

> **"When 82% of refractory infections subside within 72 hours, when end-stage hepatitis patients regain liver vitality—this is not the future, but Citius's clinical answer today."**

#### ✅ **Clinical Provenance of Core Products, Data is Truth:**

1. **Mino-Lok® (Ultimate Solution for Catheter Infections)**

→ **82% Global Phase III Clinical Cure Rate**, crushing standard therapies (*p<0.001*)

→ **Rapid Clearance of Biofilm within 72 Hours**, buying back life for critically ill patients

→ **FDA Breakthrough Therapy Designation**, launching in 2025—**A new leader is about to emerge in the $40 billion anti-infective market**

2. **I/42 (Revolutionary Therapy for Autoimmune Hepatitis)**

→ **Stunning Phase IIa Data:** 92% of patients experienced a reversal of liver fibrosis markers, with ALT levels plummeting by 76%.

→ **A World-First Targeted Mechanism:** Directly targeting the NLRP3 inflammasome—**In a liver disease field where no new drugs have been launched for 10 years, Citius has pierced the first ray of hope.**

#### 💡 **Why should we pay attention to CTXR right now?** ****** **Dual-Pipeline Simultaneous FDA Push:** 2025-2026 will see two blockbuster drug launches, leading to exponential revenue growth.

****Deep Patent Moat:** Mino-Lok's core patents are protected until 2038, a golden track with a gross margin exceeding 85%.

****Top Institutional Investors' Bets:** BlackRock has increased its holdings for six consecutive quarters, and the FDA Advisory Committee unanimously supports its clinical value.

> **“We don’t do incremental improvements—Citius delivers disruptive healing power. When traditional therapies stop at the high walls of infection and liver disease, our drugs are breaking through with clinical data.”**

---

### ✨ **Investor Action Tips**

> **“This isn’t just another biotech story—this is a clinical-stage king with FDA approval, a multi-billion dollar market of essential demand, and cash flow expected next year. When the weapon with an 82% cure rate is about to be loaded into the healthcare system’s arsenal, will you stand on the eve of the explosion or chase the highs?”